DXCM Dexcom Inc

Price (delayed)

$435.23

Market cap

$42.18B

P/E Ratio

78.42

Dividend/share

N/A

EPS

$5.55

Enterprise value

$42.56B

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in ...

Highlights
Dexcom's net income has soared by 129% YoY
The EPS has soared by 124% YoY
The quick ratio has declined by 25% year-on-year and by 14% since the previous quarter
The debt has increased by 3.5% YoY

Key stats

What are the main financial stats of DXCM
Market
Shares outstanding
96.92M
Market cap
$42.18B
Enterprise value
$42.56B
Valuations
Price to earnings (P/E)
78.42
Price to book (P/B)
19.71
Price to sales (P/S)
18.18
EV/EBIT
114.64
EV/EBITDA
92.21
EV/Sales
18.35
Earnings
Revenue
$2.32B
EBIT
$371.3M
EBITDA
$461.6M
Free cash flow
$139.5M
Per share
EPS
$5.55
Free cash flow per share
$1.44
Book value per share
$22.08
Revenue per share
$23.93
TBVPS
$48.57
Balance sheet
Total assets
$4.78B
Total liabilities
$2.64B
Debt
$1.83B
Equity
$2.14B
Working capital
$2.92B
Liquidity
Debt to equity
0.85
Current ratio
4.98
Quick ratio
4.39
Net debt/EBITDA
0.83
Margins
EBITDA margin
19.9%
Gross margin
69.3%
Net margin
22.8%
Operating margin
15.9%
Efficiency
Return on assets
11.8%
Return on equity
26.9%
Return on invested capital
8.1%
Return on capital employed
9.2%
Return on sales
16%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
1.25%
1 week
-11.25%
1 month
-21.63%
1 year
21.7%
YTD
-18.94%
QTD
-18.94%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$2.32B
Gross profit
$1.61B
Operating income
$369.2M
Net income
$529.3M
Gross margin
69.3%
Net margin
22.8%
Dexcom's net income has soared by 129% YoY
The net margin has soared by 80% YoY but it has decreased by 7% from the previous quarter
DXCM's gross profit is up by 35% year-on-year and by 7% since the previous quarter
Dexcom's revenue has increased by 27% YoY and by 7% from the previous quarter

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
P/E
78.42
P/B
19.71
P/S
18.18
EV/EBIT
114.64
EV/EBITDA
92.21
EV/Sales
18.35
The EPS has soared by 124% YoY
The company's equity rose by 42% YoY and by 7% QoQ
DXCM's P/B is 5% below its last 4 quarters average of 20.8
The stock's price to sales (P/S) is 34% more than its 5-year quarterly average of 13.6 but 6% less than its last 4 quarters average of 19.3
Dexcom's revenue has increased by 27% YoY and by 7% from the previous quarter

Efficiency

How efficient is Dexcom business performance
Dexcom's ROA has soared by 55% YoY but it has decreased by 6% from the previous quarter
The ROE is up by 36% year-on-year but it is down by 9% since the previous quarter
DXCM's return on invested capital is up by 8% since the previous quarter but it is down by 7% year-on-year
The ROS fell by 5% YoY

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 81% higher than its total liabilities
The company's total assets rose by 25% YoY and by 6% QoQ
The quick ratio has declined by 25% year-on-year and by 14% since the previous quarter
The debt is 15% less than the equity
The company's equity rose by 42% YoY and by 7% QoQ
DXCM's debt to equity is down by 28% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.